Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Strategies for Managing Alopecia Areata : Episode 2

Opinion

Video

March 4, 2025

Defining Alopecia Areata Severity and Navigating Treatment Options

Author(s):

An expert discusses how treatment for alopecia areata begins with topical/intralesional therapies for limited disease and progresses to systemic options for extensive involvement or treatment resistance. Treatment decisions are guided by disease severity, patient age, comorbidities, and treatment goals. FDA-approved systemic agents include ritlecitinib (JAK3/TEC inhibitor) and baricitinib (JAK1/2 inhibitor), which block inflammatory pathways to promote hair regrowth with favorable efficacy, though they require monitoring for potential adverse effects.

EP: 1.Alopecia Areata Clinical Presentation and Challenges in Treatment

Now Viewing

EP: 2.Defining Alopecia Areata Severity and Navigating Treatment Options

Video content above is prompted by the following:

Describe your approach to initiating treatment in patients with alopecia areata. At what point do you consider systemic treatment for your patients?
What factors guide your treatment decisions (severity, patient characteristics, patient expectations, etc)?
Briefly discuss the systemic agents that are currently FDA approved for alopecia areata, including their mechanism of action as well as efficacy and safety data.
- Ritlecitinib (JAK3/TEC inhibitor)
- Baricitinib (JAK 1/2 inhibitor)